C4 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	35.95	35.58	31.1	45.79	33.2
Revenue Growth (YoY)	1.02%	14.43%	-32.08%	37.93%	55.25%
Gross Profit	35.95	35.58	31.1	45.79	33.2
Selling, General & Admin	36.2	42.12	42.79	33.25	15.2
Research & Development	104.24	110.64	117.84	94.67	78.44
Other Operating Expenses	10.73	2.44	-	-	-
Total Operating Expenses	151.17	155.2	160.63	127.92	93.64
Operating Income	-115.22	-119.61	-129.53	-82.13	-60.45
Interest Income	10.35	14.43	3.58	0.39	0.39
Interest Expense	-	-	-2.22	-2.15	-1.23
Other Non-Operating Income (Expense)	-	-	-	-	-5.68
Total Non-Operating Income (Expense)	10.35	14.43	1.36	-1.76	-6.51
Pretax Income	-104.87	-105.19	-128.18	-83.89	-66.96
Provision for Income Taxes	-	-	-	-	-0.63
Net Income	-104.87	-105.19	-128.18	-83.89	-66.34
Net Income to Common	-104.99	-105.32	-128.18	-83.89	-66.34
Shares Outstanding (Basic)	83	69	49	46	11
Shares Outstanding (Diluted)	83	69	49	46	11
Shares Change (YoY)	19.49%	41.98%	6.13%	304.93%	728.79%
EPS (Basic)	-1.27	-1.52	-2.62	-1.82	-5.83
EPS (Diluted)	-1.27	-1.52	-2.62	-1.82	-5.83
Free Cash Flow	-99.3	-65.34	-111.44	-88.24	-67.9
Free Cash Flow Per Share	-1.20	-0.94	-2.28	-1.92	-5.97
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-320.53%	-336.14%	-416.56%	-179.39%	-182.10%
Profit Margin	-291.74%	-295.60%	-412.19%	-183.23%	-199.83%
FCF Margin	-276.24%	-183.61%	-358.36%	-192.73%	-204.55%
EBITDA	-113.26	-117.8	-127.86	-80.64	-58.83
EBITDA Margin	-315.08%	-331.04%	-411.17%	-176.13%	-177.23%
EBIT	-115.22	-119.61	-129.53	-82.13	-60.45
EBIT Margin	-320.53%	-336.14%	-416.56%	-179.39%	-182.10%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.93%

SEC Filings: 10-K · 10-Q